Alina Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alina Chen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aras N. Mattis
Liver Center, University of California San Francisco, San Francisco, CA 94143, USA
1 shared publication - Balyn Wood Zaro
University of California, San Francisco
1 shared publication Carlos Lizama Valenzuela
Department of Pediatrics, University of California, San Francisco, CA 94143, USA
1 shared publicationCarson Cable
Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, CA 94143, USA
1 shared publication- Ghmkin Hassan
University of California, San Francisco 8 Department of Surgery, Center for Bioengineering and Tissue Regeneration San Francisco, California
1 shared publication Holger Willenbring
Division of Transplant Surgery, Department of Surgery, University of California, San Francisco, CA 94143, USA
1 shared publication
Latest Publications
- 27 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (813) , eads9470
Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation
Tissue fibrosis arises from a critical imbalance between the production and breakdown of extracellular matrix (ECM) components. Whereas current strategies predominantly focus on curbing ECM production, the possibility of promoting ECM degradation to resolve fibrosis remains largely untapped. The role of hepatic stellate cells (HSCs) in ECM degradation is an intriguing area for investigation. We previously demonstrated that inhibiting acid ceramidase (aCDase) increases ceramide in HSCs to ameliorate hepatic fibrosis. Here, we uncover a key signaling pathway that promotes ECM degradation in primary human HSCs, which is dependent upon the activation of protein kinase Cα (PKCα) and the induction of matrix metalloproteinase 1 (MMP-1) through extracellular signal–regulated kinase 1/2 (ERK1/2). Genetic reduction and pharmacological inhibition with a small molecule reduced aCDase activity, leading to increased collagen degradation and hepatic fibrosis resolution in the carbon tetrachloride (CCl 4 ) and fructose, palmitate, cholesterol, and trans-fat (FPC) mouse models. Consistently, ceramide signaling correlated with ECM remodeling and degradation in patients with metabolic dysfunction–associated steatotic liver disease. The findings show that ceramide regulates ECM degradation and establish aCDase as a target for therapeutic regression of fibrosis.
- 27 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (813) , eads9470
Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation
Tissue fibrosis arises from a critical imbalance between the production and breakdown of extracellular matrix (ECM) components. Whereas current strategies predominantly focus on curbing ECM production, the possibility of promoting ECM degradation to resolve fibrosis remains largely untapped. The role of hepatic stellate cells (HSCs) in ECM degradation is an intriguing area for investigation. We previously demonstrated that inhibiting acid ceramidase (aCDase) increases ceramide in HSCs to ameliorate hepatic fibrosis. Here, we uncover a key signaling pathway that promotes ECM degradation in primary human HSCs, which is dependent upon the activation of protein kinase Cα (PKCα) and the induction of matrix metalloproteinase 1 (MMP-1) through extracellular signal–regulated kinase 1/2 (ERK1/2). Genetic reduction and pharmacological inhibition with a small molecule reduced aCDase activity, leading to increased collagen degradation and hepatic fibrosis resolution in the carbon tetrachloride (CCl 4 ) and fructose, palmitate, cholesterol, and trans-fat (FPC) mouse models. Consistently, ceramide signaling correlated with ECM remodeling and degradation in patients with metabolic dysfunction–associated steatotic liver disease. The findings show that ceramide regulates ECM degradation and establish aCDase as a target for therapeutic regression of fibrosis.